US Edition
Published • loading... • Updated
Bayer’s Asundexian FXIa Inhibitor Demonstrates Reduction in Ischemic Stroke in OCEANIC-STROKE Study
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Endovascular TodayReposted by 
Cardiac Interventions Today
Cardiac Interventions TodayBayer’s Asundexian FXIa Inhibitor Demonstrates Reduction in Ischemic Stroke in OCEANIC-STROKE Study
April 17, 2026—The results from the OCEANIC-STROKE study were published by Mukul Sharma, MD, et al in The New England Journal of Medicine (NEJM; 2026;394:1467-1479). As stated in NEJM, the study investigated the safety and efficacy of administering the oral factor XIa inhibitor asundexian (Bayer) at a daily dose of 50 mg in addition to antiplatelet therapy to reduce the risk of recurrent ischemic stroke in patients after a noncardioembolic ische…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
